FDA Grants Fast Track Designation to FLQ-101 for Retinopathy of Prematurity

FDA Grants Fast Track Designation to FLQ-101 for Retinopathy of Prematurity

Developments in retinal therapies continue to make strides as regulatory bodies take notice of critical unmet needs in eye care. For the inherited retinal disease (IRD) and broader eye care communities, tracking advancements in retinal vascular health and protective treatments offers valuable insight into the evolving landscape of ophthalmic drug development.

According to Ophthalmology Times Europe, the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to FLQ-101, the lead asset developed by biopharmaceutical company FELIQS, for the prevention of retinopathy of prematurity (ROP). FLQ-101 is a once-daily oral or intravenous small molecule solution designed to target lipid oxidation. The therapy aims to enhance the physiologic response of vascularization in the retina while offering protection against inflammation and abnormal neovascularization.

This regulatory milestone highlights the ongoing focus on addressing severe ocular conditions where preventative options are currently lacking. According to company statements reported by Ophthalmology Times Europe, there are no approved preventative treatments available for ROP, creating a significant medical gap for vulnerable patient populations. The Fast Track designation is intended to facilitate the development and expedite the review of investigational medicines that address serious conditions and fill unmet medical needs, granting developers closer communication access to the FDA.

Looking ahead, FELIQS has announced plans to advance the clinical evaluation of FLQ-101 by initiating a Phase 1b/2 study—known as the tROPhy-1 study—in both the United States and Japan. As clinical trials progress, the community will continue to monitor how these targeted approaches to retinal health and vascular protection unfold.